Advanced Liver Fibrosis Correlates With Impaired Efficacy of Pfizer‐BioNTech COVID‐19 Vaccine in Medical Employees
Asher Shafrir, Johnny Amer, David Hakimian, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Ashraf Imam, Abed Khalaileh, Rifaat Safadi – 10 February 2022 – The Pfizer‐BioNTech coronavirus disease 2019 (COVID‐19) vaccine has been offered to nonallergic ≥16‐year‐old Israeli adults since December 19, 2020. Data regarding factors associated with vaccine ineffectiveness are limited. The aim of this study is to assess the impact of hepatic fibrosis on the efficacy of the BioNTech vaccine.